GE Healthcare is one step closer to getting its positron emission tomography(PET) imaging agent to market. Today, the company announced that the U.S. Food and Drug Administration has accepted its application to review flutemetamol, a PET amyloid imaging agent used in the visual detection of beta amyloid in the brains of patients being evaluated for Alzheimer’s disease and related cognitive disorders. Additionally, the European regulatory body, the European Medicines Agency, will also consider GE’s application for review.